Puma Biotechnology (PBYI) Receivables (2016 - 2026)

Puma Biotechnology has reported Receivables for 11 years, with the latest figure at $26.3 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables rose 2.26% year-over-year to $26.3 million; the trailing twelve-month figure through Mar 2026 stood at $26.3 million (up 2.26% YoY), and the FY2025 full-year result was $53.7 million, up 67.61% from the prior year.
• Receivables for Q1 2026 stood at $26.3 million, down from $53.7 million in the prior quarter.
• The five-year high for Receivables was $54.6 million in Q3 2024, with the low at $24.6 million in Q1 2024.
• Historically, Receivables has averaged $33.7 million across 5 years, with a median of $31.2 million in 2023.
• Annual changes were most pronounced in 2024 — Receivables jumped 88.59% — and 2025, when it plunged 38.57%.
• Puma Biotechnology's Receivables stood at $40.4 million in 2022, then grew by 18.56% to $47.8 million in 2023, then sank by 33.08% to $32.0 million in 2024, then surged by 67.61% to $53.7 million in 2025, then sank by 50.93% to $26.3 million in 2026.
• The last three Receivables figures came in at $26.3 million (Q1 2026), $53.7 million (Q4 2025), and $33.6 million (Q3 2025), per Business Quant data.